45,000-Patient Registry Yields Atherothrombotic Disease Risk Factors
Major Finding: Four-year follow-up of a large, atherothrombotic-disease database found four factors that strongly determine risk for new ischemic events: polyvascular disease, ischemic event within the past year, any history of an ischemic event, and on treatment for diabetes.
Data Source: The REACH registry, which enrolled in 44 countries and tracked ischemic events in 45,227 patients with established atherothrombotic disease or multiple risk factors for 4 years during 2003-2008.
Disclosures: REACH is partially sponsored by Sanofi-Aventis and Bristol-Myers Squibb. Dr. Bhatt reported receiving research grants from AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi-Aventis, and The Medicines Company.
From the annual congress of the European Society of Cardiology
In a multivariable regression model, polyvascular disease at baseline linked with a twofold increased risk for an ischemic event during follow-up, compared with enrollees with risk factors only. Patients with a history of a recent ischemic event had a 70% higher risk for a follow-up event compared with enrollees without an event history. Patients with diabetes at enrollment had a 44% increased risk for a follow-up event compared with participants without diabetes, which did match the increased risk from an older ischemic event. Heart failure also appeared as a strong risk factor.
“Our analysis provides simple criteria for assessing the risk of cardiovascular events in stable outpatients,” Dr. Bhatt said.
Concurrently with Dr. Bhatt’s report, the results were published online (JAMA 2010 Aug. 30 [doi: 10.1001/jama.2010.1322]). The REACH registry is partially sponsored by Sanofi-Aventis and Bristol-Myers Squibb. Dr. Bhatt reported receiving research grants from AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, Sanofi-Aventis, and The Medicines Company.
